Skip to content

Mineralys Therapeutics

US · MLYS #2760 by market cap Listed 2023
13.66 -0.50 -3.53%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

About Mineralys Therapeutics

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.

Founded
2019
CEO
Mr. Jon Congleton
Employees
76
Headquarters
Radnor, Pennsylvania, United States of America
Fiscal year end
12-31
Website
mineralystx.com

Company profile

Exchange
US
Symbol
MLYS
Market-cap rank
#2760
Listing date
2023-02-10
Market cap
1.21B
Float cap
911.75M
Shares out
88.56M
Float shares
66.75M

Sectors & themes

Browse all sectors & themes

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

Mineralys Therapeutics discussion 0 comments

Add a comment